Total trials
262
Active
24
Phase 3
54
Total enrollment
338,074
Pipeline matrix
Showing 40 of 53 active programs · click any cell for trials
| Intervention | Early Phase 1 | Phase 1 | Phase 2 | Phase 3 | Phase 4 | N/A | Total |
|---|---|---|---|---|---|---|---|
| Cabotegravir | — | — | 8 | ||||
| CAB LA | — | — | — | 8 | |||
| Rilpivirine | — | — | — | 6 | |||
| Emtricitabine | — | — | — | — | 3 | ||
| Cabotegravir - Injectable Suspension | — | — | — | — | — | 3 | |
| Rilpivirine - Injectable Suspension | — | — | — | — | — | 3 | |
| CAB ULA | — | — | — | — | 2 | ||
| Dolutegravir | — | — | 19 | ||||
| Fostemsavir | — | — | — | 3 | |||
| BMS-663068 | — | — | — | 15 | |||
| Cabotegravir Injectable Suspension | — | — | — | — | — | 3 | |
| Rilpivirine Injectable Suspension | — | — | — | — | — | 3 | |
| RPV LA | — | — | — | — | 3 | ||
| Bictegravir | — | — | — | — | — | 1 | |
| Tenofovir alafenamide | — | — | — | — | — | 1 | |
| RPV ULA | — | — | — | — | — | 1 | |
| CAB LA + RPV LA | — | — | — | — | — | 1 | |
| Oral ART | — | — | — | — | — | 1 | |
| 2 NRTIs plus an INI, NNRTI, or PI | — | — | — | — | — | 1 | |
| ABC/DTG/3TC STR - | — | — | — | — | — | 1 | |
| Lamivudine | — | 10 | |||||
| DTG | — | — | 10 | ||||
| rHuPH20 | — | — | — | — | 4 | ||
| VH4524184 | — | — | — | — | 6 | ||
| VH3810109 | — | — | — | — | 3 | ||
| Oral CAB | — | — | — | — | 2 | ||
| Standard of care | — | — | — | — | — | 1 | |
| IM CAB LA | — | — | — | — | — | 1 | |
| New formulation of CAB LA | — | — | — | — | — | 1 | |
| Dolutegravir / Lamivudine | — | — | — | — | — | 1 | |
| Dolutegravir/Rilpivirine FDC | — | — | — | — | — | 1 | |
| RPV | — | — | — | — | 4 | ||
| VH4011499 | — | — | — | — | 3 | ||
| VH4004280 | — | — | — | — | 3 | ||
| Midazolam | — | — | — | — | — | 4 | |
| Cabotegravir 200 mg/mL | — | — | — | — | — | 2 | |
| VH4770359 | — | — | — | — | — | 1 | |
| VH4527079 | — | — | — | — | — | 1 | |
| Oral VH4524184 | — | — | — | — | — | 1 | |
| VH4524184 Formulation A SC | — | — | — | — | — | 1 |
13 more active programs hidden
Next readouts
- 2016-08-18
- 2018-05-29
- 2018-08-30
- 2019-06-06
- 2025-07-15
- 2026-04-15
- 2026-05-22
- 2026-06-01
- 2026-06-09
- 2026-08-19
Top conditions
- HIV Infections128
- Infection, Human Immunodeficiency Virus96
- Infection, Human Immunodeficiency Virus I17
- HIV Infection12
- HIV8
- Healthy5
- Infections, Human Immunodeficiency Virus and Herpesviridae5
- AIDS4
Frequently asked questions about ViiV Healthcare
- How many clinical trials does ViiV Healthcare have on ClinicalTrials.gov?
- ViiV Healthcare is listed as the lead sponsor on 262 clinical trials in ClinicalTrials.gov, 24 of which are currently active (recruiting, enrolling, or ongoing).
- How many of ViiV Healthcare's trials are in Phase 3?
- 54 of ViiV Healthcare's trials are in Phase 3, spread across 53 active drug programs.
- What therapeutic areas does ViiV Healthcare focus on?
- ViiV Healthcare's most-studied conditions on ClinicalTrials.gov are HIV Infections, Infection, Human Immunodeficiency Virus, Infection, Human Immunodeficiency Virus I, HIV Infection, HIV.
- When are ViiV Healthcare's next clinical trial readouts?
- ViiV Healthcare has 10 upcoming primary-completion readouts tracked here; the soonest is “Attachment Inhibitor Comparison in Heavily Treatment Experienced Patients”, expected around 2016-08-18.